Gene expression profiling in autoantibody-positive patients with arthralgia predicts development of arthritis

Arthritis and Rheumatism

Volumn 62, Issue 3, 2010, Pages 694-704

  Van Baarsen, Lisa G M ^a,b   Bos, Wouter H ^c   Rustenburg, François ^b   Van Der Pouw Kraan, Tineke C T M ^b   Wolbink, Gerrit Jan J ^c   Dijkmans, Ben A C ^b   Van Schaardenburg, Dirkjan ^b   Verweij, Cornelis L ^b  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

^b VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^c JAN VAN BREEMEN INSTITUTE   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICITRULLINATED PROTEIN ANTIBODY; AUTOANTIBODY; BIOLOGICAL MARKER; IMMUNOGLOBULIN M; INTERFERON; RHEUMATOID FACTOR; UNCLASSIFIED DRUG;

ADULT; ARTHRALGIA; ARTICLE; CELL MIGRATION; COMPARATIVE STUDY; CONTROLLED STUDY; DISEASE COURSE; FEMALE; GENE EXPRESSION; GENETIC HETEROGENEITY; HEMATOPOIESIS; HUMAN; HUMORAL IMMUNITY; MAJOR CLINICAL STUDY; MALE; PATHOPHYSIOLOGY; PREDICTION; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; RISK ASSESSMENT;

ARTHRALGIA; ARTHRITIS, RHEUMATOID; AUTOANTIBODIES; B-LYMPHOCYTES; FEMALE; GENE EXPRESSION; HEMATOPOIESIS; HUMANS; INTERFERONS; MALE; MIDDLE AGED; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; POLYMERASE CHAIN REACTION; RHEUMATOID FACTOR;

EID: 77649146866     PISSN: 00043591     EISSN: 15290131     Source Type: Journal    
DOI: 10.1002/art.27294     Document Type: Article

References (46)

1. Quinn MA, Conaghan PG, Emery P. The therapeutic approach of early intervention for rheumatoid arthritis: what is the evidence? Rheumatology (Oxford) 2001;40:1211-20.
2. O'Dell JR. Treating rheumatoid arthritis early: a window of opportunity? Arthritis Rheum 2002;46:283-5.
3. Mottonen T, Hannonen P, Korpela M, Nissila M, Kautiainen H, Ilonen J, et al. Delay to institution of therapy and induction of remission using single-drug or combination disease-modifying antirheumatic drug therapy in early rheumatoid arthritis. Arthritis Rheum 2002;46:894-8.
4. Goekoop-Ruiterman YP, de Vries-Bouwstra JK, Allaart CF, van Zeben D, Kerstens PJ, Hazes JM, et al. Comparison of treatment strategies in early rheumatoid arthritis: a randomized trial. Ann Intern Med 2007;146:406-15.
5. Emery P, McInnes IB, van Vollenhoven R, Kraan MC. Clinical identification and treatment of a rapidly progressing disease state in patients with rheumatoid arthritis. Rheumatology (Oxford) 2008;47:392-8.
6. Aho K, Palosuo T, Raunio V, Puska P, Aromaa A, Salonen JT. When does rheumatoid disease start? Arthritis Rheum 1985;28: 485-9.
7. Aho K, von Essen R, Kurki P, Palosuo T, Heliovaara M. Antikeratin antibody and antiperinuclear factor as markers for subclinical rheumatoid disease process. J Rheumatol 1993;20:1278-81.
8. Aho K, Palosuo T, Heliovaara M, Knekt P, Alha P, von Essen R. Antifilaggrin antibodies within "normal" range predict rheumatoid arthritis in a linear fashion. J Rheumatol 2000;27:2743-6.
9. Rantapaa-Dahlqvist S, de Jong BA, Berglin E, Hallmans G, Wadell G, Stenlund H, et al. Antibodies against cyclic citrullinated peptide and IgA rheumatoid factor predict the development of rheumatoid arthritis. Arthritis Rheum 2003;48:2741-9.
10. Nielen MM, van Schaardenburg D, Reesink HW, van de Stadt RJ, van der Horst-Bruinsma IE, de Koning MH, et al. Specific autoantibodies precede the symptoms of rheumatoid arthritis: a study of serial measurements in blood donors. Arthritis Rheum 2004;50:380-6.
11. Jorgensen KT, Wiik A, Pedersen M, Hedegaard CJ, Vestergaard BF, Gislefoss RE, et al. Cytokines, autoantibodies and viral antibodies in premorbid and postdiagnostic sera from patients with rheumatoid arthritis: case-control study nested in a cohort of Norwegian blood donors. Ann Rheum Dis 2008;67:860-6.
12. Bos WH, Wolbink GJ, Boers M, Tijhuis GJ, de Vries N, van der Horst-Bruinsma IE, et al. Arthritis development in arthralgia patients is strongly associated with anti-citrullinated protein antibody status: a prospective cohort study. Ann Rheum Dis 2009. E-pub ahead of print.
13. Lundberg K, Nijenhuis S, Vossenaar ER, Palmblad K, van Venrooij WJ, Klareskog L, et al. Citrullinated proteins have increased immunogenicity and arthritogenicity and their presence in arthritic joints correlates with disease severity. Arthritis Res Ther 2005;7:R458-67.
14. Kuhn KA, Kulik L, Tomooka B, Braschler KJ, Arend WP, Robinson WH, et al. Antibodies against citrullinated proteins enhance tissue injury in experimental autoimmune arthritis. J Clin Invest 2006;116:961-73.
15. Quinn MA, Gough AK, Green MJ, Devlin J, Hensor EM, Greenstein A, et al. Anti-CCP antibodies measured at disease onset help identify seronegative rheumatoid arthritis and predict radiological and functional outcome. Rheumatology (Oxford) 2006;45:478-80.
16. Hill JA, Bell DA, Brintnell W, Yue D, Wehrli B, Jevnikar AM, et al. Arthritis induced by posttranslationally modified (citrullinated) fibrinogen in DR4-IE transgenic mice. J Exp Med 2008;205: 967-79.
17. Klareskog L, Alfredsson L, Rantapaa-Dahlqvist S, Berglin E, Stolt P, Padyukov L. What precedes development of rheumatoid arthritis? Ann Rheum Dis 2004;63 Suppl 2:ii28-31.
18. Klareskog L, Ronnelid J, Lundberg K, Padyukov L, Alfredsson L. Immunity to citrullinated proteins in rheumatoid arthritis. Annu Rev Immunol 2008;26:651-75.
19. Hill JA, Southwood S, Sette A, Jevnikar AM, Bell DA, Cairns E. Cutting edge: the conversion of arginine to citrulline allows for a high-affinity peptide interaction with the rheumatoid arthritisassociated HLA-DRB1*0401 MHC class II molecule. J Immunol 2003;171:538-41.
20. Hueber WJ, Tomooka BH, Deane K, Parrish LA, Holers VM, Robinson WH. Autoantibody profiling in pre-disease RA samples [abstract]. Arthritis Rheum 2007;9 Suppl 56;S517.
21. Rantapaa-Dahlqvist S, Boman K, Tarkowski A, Hallmans G. Up regulation of monocyte chemoattractant protein-1 expression in anti-citrulline antibody and immunoglobulin M rheumatoid factor positive subjects precedes onset of inflammatory response and development of overt rheumatoid arthritis. Ann Rheum Dis 2007;66:121-3.
22. Bos WH, Ursum J, de Vries N, Bartelds GM, Wolbink GJ, Nurmohamed MT, et al. The role of the shared epitope in arthralgia with anti-cyclic citrullinated peptide antibodies (anti-CCP), and its effect on anti-CCP levels. Ann Rheum Dis 2008;67: 1347-50.
23. Van der Heijde DM, van 't HM, van Riel PL, van de Putte LB. Development of a disease activity score based on judgment in clinical practice by rheumatologists. J Rheumatol 1993;20:579-81.
24. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31:315-24.
25. Klein F, Janssens MB. Standardisation of serological tests for rheumatoid factor measurement. Ann Rheum Dis 1987;46: 674-80.
26. Van der Pouw Kraan TC, Wijbrandts CA, van Baarsen LG, Voskuyl AE, Rustenburg F, Baggen JM, et al. Rheumatoid arthritis subtypes identified by genomic profiling of peripheral blood cells: assignment of a type I interferon signature in a subpopulation of patients. Ann Rheum Dis 2007;66:1008-14.
27. Demeter J, Beauheim C, Gollub J, Hernandez-Boussard T, Jin H, Maier D, et al. The Stanford Microarray Database: implementation of new analysis tools and open source release of software. Nucleic Acids Res 2007;35(Database issue):D766-70.
28. Van Baarsen LG, van der Pouw Kraan TC, Kragt JJ, Baggen JM, Rustenburg F, Hooper T, et al. A subtype of multiple sclerosis defined by an activated immune defense program. Genes Immun 2006;7:522-31.
29. Tusher VG, Tibshirani R, Chu G. Significance Analysis of Microarrays applied to the ionizing radiation response. Proc Natl Acad Sci U S A 2001;98:5116-21.
30. Eisen MB, Spellman PT, Brown PO, Botstein D. Cluster analysis and display of genome-wide expression patterns. Proc Natl Acad Sci U S A 1998;95:14863-8.
31. Tibshirani R, Hastie T, Narasimhan B, Chu G. Diagnosis of multiple cancer types by shrunken centroids of gene expression. Proc Natl Acad Sci U S A 2002;99:6567-72.
32. Thomas PD, Campbell MJ, Kejariwal A, Mi H, Karlak B, Daverman R, et al. PANTHER: a library of protein families and subfamilies indexed by function. Genome Res 2003;13:2129-41.
33. Thomas PD, Kejariwal A, Guo N, Mi H, Campbell MJ, Muruganujan A, et al. Applications for protein sequence-function evolution data: mRNA/protein expression analysis and coding SNP scoring tools. Nucleic Acids Res 2006;34(Web Server issue): W645-50.
34. Bos WH, Dijkmans BA, Boers M, van de Stadt R, van Schaardenberg D. Effect of dexamethasone on autoantibody levels and arthritis development in arthralgia patients: a randomized trial. Ann Rheum Dis 2009. E-pub ahead of print.
35. Luft T, Pang KC, Thomas E, Hertzog P, Hart DN, Trapani J, et al. Type I IFNs enhance the terminal differentiation of dendritic cells. J Immunol 1998;161:1947-53.
36. Santini SM, Lapenta C, Logozzi M, Parlato S, Spada M, Di Pucchio T, et al. Type I interferon as a powerful adjuvant for monocyte-derived dendritic cell development and activity in vitro and in Hu-PBL-SCID mice. J Exp Med 2000;191:1777-88.
37. Huang X, Shen N, Bao C, Gu Y, Wu L, Chen S. Interferoninduced protein IFIT4 is associated with systemic lupus erythematosus and promotes differentiation of monocytes into DC-like cells. Arthritis Res Ther 2008;10:R91.
38. Stabler T, Piette JC, Chevalier X, Marini-Portugal A, Kraus VB. Serum cytokine profiles in relapsing polychondritis suggest monocyte/ macrophage activation. Arthritis Rheum 2004;50:3663-7.
39. Hueber W, Tomooka BH, Zhao X, Kidd BA, Drijfhout JW, Fries JF, et al. Proteomic analysis of secreted proteins in early rheumatoid arthritis: anti-citrulline autoreactivity is associated with up regulation of proinflammatory cytokines. Ann Rheum Dis 2007; 66:712-9.
40. Fukao T, Frucht DM, Yap G, Gadina M, O'Shea JJ, Koyasu S. Inducible expression of Stat4: dendritic cells and macrophages and its critical role in innate and adaptive immune responses. J Immunol 2001;166:4446-55.
41. Remmers EF, Plenge RM, Lee AT, Graham RR, Hom G, Behrens TW, et al. STAT4 and the risk of rheumatoid arthritis and systemic lupus erythematosus. N Engl J Med 2007;357:977-86.
42. Pruenster M, Rot A. Throwing light on DARC. Biochem Soc Trans 2006;34(Pt 6):1005-8.
43. Fukuma N, Akimitsu N, Hamamoto H, Kusuhara H, Sugiyama Y, Sekimizu K. A role of the Duffy antigen for the maintenance of plasma chemokine concentrations. Biochem Biophys Res Commun 2003;303:137-9.
44. Edwards JC, Szczepanski L, Szechinski J, Filipowicz-Sosnowska A, Emery P, Close DR, et al. Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N Engl J Med 2004;350:2572-81.
45. Wagner U, Kaltenhauser S, Pierer M, Wilke B, Arnold S, Hantzschel H. B lymphocytopenia in rheumatoid arthritis is associated with the DRB1 shared epitope and increased acute phase response. Arthritis Res 2002;4:R1.
46. Bos WH, Wolbink GJ, Boers M, Tijhuis GJ, de Vries N, Bruinsma IE, et al. Arthritis development in prospectively followed arthralgia patients is dependent on anti-citrullinated protein antibody status [abstract]. Arthritis Rheum 2008;58 Suppl:S290.